The IgA nephropathy (IgAN) market is entering the most competitive stretch in its history. After decades of supportive-care-only management, a wave of disease-modifying therapies is reaching approval and reimbursement decisions at once — and CI teams that treat 2026 like 2024 will be caught flat.
Why the landscape is shifting now
Three forces are converging: targeted therapies moving from trial to launch, payers building coverage frameworks for a condition that previously had few branded options, and nephrology prescribers being asked to sequence treatments for the first time. Each force changes the commercial question your brief has to answer.
The comparator set is expanding fast
What used to be a short list is now a sequencing problem. Understanding mechanism, trial readouts, and expected label breadth for each entrant is table stakes; the differentiated read is on how prescribers will actually order therapy once more than one option is reimbursed.
What CI teams need before the launch wave
- A drug-by-drug commercial posture read across the emerging comparator set.
- Payer signposting: which coverage criteria and step edits are likely, and where.
- A prescriber-pathway view of how sequencing decisions will be made.
AXLRx builds this as a custom competitive intelligence brief — scoped to your asset and market, sourced from primary evidence, delivered in 72 hours.